Quentis Therapeutics Appoints Magram Chief Scientific Officer

Jeanne Magram has been appointed chief scientific officer of cancer immunotherapy developer Quentis Therapeutics. Before joining New York-based Quentis, Magram was chief scientific officer of Northern Biologics, a Toronto biotech company. Her experience also includes posts at Pfizer (NYSE: [[ticker:PFE]]) and Boeringer Ingelheim. In February, Quentis raised $48 million in a Series A financing round to back preclinical drugs intended to block a cellular stress response that disrupts the immune system’s ability to fight cancer.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.